What's in ACCORD HLTHCARE's pipeline?

ACCORD HLTHCARE has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ACCORD HLTHCARE's portfolio?

Top competitors by shared drug class: , Eisai, Nihon Schering K.K., Pfizer, R-Pharm Us Llc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/accord-hlthcare.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

ACCORD HLTHCARE — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACCORD HLTHCARE pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Jevtana Kit	cabazitaxel	marketed	Microtubule Inhibitor	Tubulin beta	Oncology	2010-01-01
Gemzar	Gemcitabine Hydrochloride	marketed	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	Oncology	1996-01-01
Gemzar	gemcitabine	marketed	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	Oncology	1996-01-01

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2030-06-28 — Gemzar · 12403086 · Formulation · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-04-15 — Gemzar · 8679094 · Formulation · US
2033-07-01 — Gemzar · 9241948 · Formulation · US
2034-08-19 — Gemzar · 12447241 · Formulation · US
2034-08-19 — Gemzar · 10729823 · Formulation · US

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Eisai · 1 shared drug class
Nihon Schering K.K. · 1 shared drug class
Pfizer · 1 shared drug class
R-Pharm Us Llc · 1 shared drug class
Spectrum Pharms · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ACCORD HLTHCARE:

Cite this brief

Drug Landscape (2026). ACCORD HLTHCARE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/accord-hlthcare. Accessed 2026-05-16.